<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306109</url>
  </required_header>
  <id_info>
    <org_study_id>AUSLMO_0001_SLA</org_study_id>
    <nct_id>NCT02306109</nct_id>
  </id_info>
  <brief_title>Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>ermoSla</acronym>
  <official_title>Effects of Motor Rehabilitation Treatment on Disability and Quality of Life in Amyotrophic Lateral Sclerosis (ALS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Unita' Sanitaria Locale Di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>S. Anna Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Unità Sanitaria Locale Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Unità Sanitaria Locale Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Unita' Sanitaria Locale Di Modena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ErmoSLA is a multicentric, randomized, controlled trial to compare effects of an &quot;intensive&quot;&#xD;
      or &quot;standard&quot; motor rehabilitation treatment on motor disability in people with ALS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicentric, randomized, controlled trial to compare effects of standard&#xD;
      versus intensive motor rehabilitation treatment for people with ALS.&#xD;
&#xD;
      Eligible patients are going to be randomly assigned to the Standard or Intensive treatment&#xD;
      (controlling for ALSFRSR rates at enrollment, age and site of onset). Randomization ratio is&#xD;
      1:1.&#xD;
&#xD;
      Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one)&#xD;
      for 10 weeks for a total of 20 sessions. The program consists of exercises for aerobic&#xD;
      endurance, reinforcement at low load and stretching. At the end of the 20 sessions patient&#xD;
      and caregiver are going to continue activity with supervision through regular follow up.&#xD;
&#xD;
      Intensive treatment is characterized by an increased volume of the above mentioned exercises:&#xD;
      5 sessions/week (45 minutes each one) for 10 weeks for a total of 50 sessions. At the end of&#xD;
      the 50 sessions patient and caregiver are going to continue activity with supervision through&#xD;
      regular follow up.&#xD;
&#xD;
      Collection and analysis of data&#xD;
&#xD;
      Recruitment: during the first 18 months of the study. Outcome measures: evaluated at&#xD;
      T0-T3-T6-T9-T12-T15-T18-T21-T24. Rating scales will be administered by a neurologist in singe&#xD;
      blind method with respect to the treatment.&#xD;
&#xD;
      Data collection will be done through an ad hoc Case Report Form and entered into a database&#xD;
      on a dedicated website.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in ALSFRS R</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complications related to the disease: pressure sores, hospitalizations, infections</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived quality of care</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheostomy free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to supporting procedures (NIV and PEG)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function: measured by FVC</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: measured by McGill and ALSAQ40 scales</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease symptoms (fatigue) measured with FSS</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression measured by Beck Inventory Scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Standard motor rehabilitation treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive motor rehabilitation treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard motor rehabilitation treatment</intervention_name>
    <description>Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up</description>
    <arm_group_label>Standard motor rehabilitation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intensive motor rehabilitation treatment</intervention_name>
    <description>Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up</description>
    <arm_group_label>Intensive motor rehabilitation treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of possible, probable or definite ALS according to the Revised El Escorial&#xD;
             Criteria&#xD;
&#xD;
          -  Time from diagnosis &lt;18 months at screening.&#xD;
&#xD;
          -  Forced vital capacity (FVC)&gt; 50% at screening&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Patients will be required to take the full dose of Riluzole, but not assuming Riluzole do&#xD;
        not constitute a criterion for exclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolment in any other clinical trial in the three months prior to screening&#xD;
&#xD;
          -  Tracheostomy or NIV for&gt; 23h/day for 14 consecutive days at screening.&#xD;
&#xD;
          -  Diagnosis of severe neurodegenerative diseases in addition to the ALS&#xD;
&#xD;
          -  Diagnosis of severe heart disease, current neoplasia, any unstable medical condition&#xD;
             that contraindicates an intensive rehabilitation treatment&#xD;
&#xD;
          -  State of pregnancy or breastfeeding&#xD;
&#xD;
          -  Residency outside Emilia-Romagna Region&#xD;
&#xD;
          -  Lack of multidisciplinary follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Vinceti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Public Health Department, University of Modena and Reggio Emilia (IT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neuroscience, S. Anna Hospital</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neuroscience, S.Agostino-Estense Hospital</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neuroscience, IRCCS Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>August 5, 2018</last_update_submitted>
  <last_update_submitted_qc>August 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Unita' Sanitaria Locale Di Modena</investigator_affiliation>
    <investigator_full_name>Jessica Mandrioli</investigator_full_name>
    <investigator_title>MD, Department of Neuroscience, St. Agostino-Estense Hospital, Modena (IT)</investigator_title>
  </responsible_party>
  <keyword>Motor Rehabilitation Treatment</keyword>
  <keyword>Intensive versus standard</keyword>
  <keyword>Motor Disability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

